30% off. Use code SUMMER30 at checkout for 30% off for 12 months on Pro and Premium subscriptions. Subscribe now

Luke Beshar

Insider profile

Currently holds positions in Protara Therapeutics Inc, Trillium Therapeutics Inc and Regenxbio Inc

Performance

Overall performance
2.4

Performance over holding periods
2.4
30 days 90 days 120 days
Average return 7% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
3 100% Buy
34 71% Buy
47 69% Buy

Positions

Position Company Period
Chairman of the Board Protara Therapeutics Inc Jan. 9, 2020 -
Independent Director Trillium Therapeutics Inc March 10, 2014 -
Independent Director Regenxbio Inc April 1, 2015 -
Chairman of the Board Entera Bio Ltd Dec. 1, 2016 - Aug. 9, 2018
Director Entera Bio Ltd Dec. 1, 2015 - Dec. 1, 2016
Chief Financial Officer, Executive Vice President Shire-Nps Pharmaceuticals Inc Jan. 1, 2011 - Feb. 20, 2015

Luke Beshar's trades of Protara Therapeutics Inc's stock


Loading...
Purchase Sale Planned purchase Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value
Number of shares Price Value Details
2022-07-05 2022-06-30 B Purchase
20,552 +9.4%
96.23
US$876,067
20,552 +9.4% 96.23 US$876,067
2022-03-16 2022-03-14 B Purchase
41,068 +44.4%
127.79
US$2,551,518
41,068 +44.4% 127.79 US$2,551,518
2022-03-14 2022-03-10 B Purchase
35,217 -46.3%
235.87
US$532,631
35,217 -46.3% 235.87 US$532,631